Prelude Capital Management’s Heron Therapeutics HRTX Stock Holding History

Prelude Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,000	Closed	-$29K	–	2052
2020 Q2	$29K	Buy	2,000 +1,700	+567%	+$27.9K	﹤0.01%	1304
2020 Q1	$4K	Buy	+300	New	+$5.64K	﹤0.01%	1255
2016 Q4	–	Sell	-2,000	Closed	-$34K	–	1655
2016 Q3	$34K	Buy	+2,000	New	+$37.1K	﹤0.01%	1176

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Prelude Capital Management's HRTX Position: Q2 2022 in Review

Prelude Capital Management sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 20,600 shares — an estimated $118K sold.

Prelude Capital Management first reported a position in HRTX in Q2 2014 and held it in 13 quarters. The position peaked at $1.31M in Q2 2018. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

Prelude Capital Management reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
Prelude Capital Management sold 20,600 Heron Therapeutics shares in Q2 2022, an estimated $118K.
Prelude Capital Management first reported a position in Heron Therapeutics in Q2 2014 and held it in 13 quarters.
Prelude Capital Management's Heron Therapeutics position peaked at $1.31M in Q2 2018.
174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.